NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Institut Claudius Regaud
Peking University Cancer Hospital & Institute
Prisma Health-Upstate
Children's National Research Institute
M.D. Anderson Cancer Center
Anhui Provincial Cancer Hospital
Georgetown University
Peking University Cancer Hospital & Institute
Emory University
St. Jude Children's Research Hospital
Zhejiang University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center